Evoke Pharma (EVOK) Appoints Greg Pyszczymuka to its Board

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke’s commercial strategy and growth potential.

Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the company to operational profitability. Under his leadership, Aytu has strengthened its financial performance and achieved sustainable revenue growth over the past two years. His expertise in expanding prescription product revenues and optimizing commercial operations has contributed to Aytu’s continued financial momentum.

“We are excited to welcome Greg to our Board of Directors,” said Matt D'Onofrio, CEO of Evoke Pharma. “His deep expertise in commercial strategy and revenue optimization, coupled with his success in driving robust financial performance, aligns perfectly with Evoke’s ongoing growth trajectory. As we continue expanding access to Gimoti®, Greg’s insights will be instrumental in helping us strengthen our market presence and enhance shareholder value.”

Prior to Aytu, he held senior commercial leadership roles at Neos Therapeutics, including Vice President, Commercial Strategy & Market Access, and Vice President, Commercial. Over his 20-year career, he has built and led high-performing teams across sales, brand management, managed markets, and business development. His career also includes leadership positions at Aqua Pharmaceuticals (an Almirall company), Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.

Mr. Pyszczymuka commented, “I am honored to join Evoke’s Board of Directors at this exciting time. Evoke’s commitment to addressing the needs of patients with diabetic gastroparesis resonates deeply with me, and I look forward to leveraging my experience to help drive commercial success. With Gimoti® gaining market traction, I see tremendous opportunities to further expand adoption and accelerate growth.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Visit www.EvokePharma.com for more information.

Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter

You May Also Be Interested In

• Abbott settles preterm formula NEC lawsuits for $670 million
• Hertz Global amends voting agreement with CK Amarillo after lawsuit
• James Hardie sells Fermacell unit to Holcim for €840 million